Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Subscribe to JNMT RSS feeds
Research ArticleBrief Communication

Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review

Emran Askari, Soroush Zarehparvar Moghadam, Damian Wild, Ebrahim Delpassand, Sergio Baldari, Bernhard Nilica, Philipp E. Hartrampf, Grace Kong, Chiara Maria Grana, Martin Alexander Walter, Francesca Capoccetti, Pashtoon Murtaza Kasi and Jonathan Strosberg
Journal of Nuclear Medicine Technology March 2023, 51 (1) 22-25; DOI: https://doi.org/10.2967/jnmt.122.264904
Emran Askari
1Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soroush Zarehparvar Moghadam
1Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damian Wild
2ENETS Center of Excellence, Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ebrahim Delpassand
3Department of Clinical Nuclear Medicine, Excel Diagnostics Imaging Clinic, Houston, Texas;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio Baldari
4Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, University of Messina, Messina, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernhard Nilica
5Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp E. Hartrampf
6Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Kong
7Sir Peter MacCallum Department of Oncology and Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiara Maria Grana
8Division of Nuclear Medicine, European Institute of Oncology, IRCCS, Milan, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Alexander Walter
9Nuclear Medicine and Molecular Division, Geneva Medical Hospital, Geneva, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Capoccetti
10UOC Nuclear Medicine–PET Center–Single Regional Center for Radiometabolic Therapy, Department of Radiological Diagnosis and Services, ASUR Marche Area Vasta 3, Macerata, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pashtoon Murtaza Kasi
11Meyer Cancer Center and Englander Institute of Precision Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Strosberg
12Neuroendocrine Tumor Division, Gastrointestinal Department, Moffitt Cancer Center, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Merkel cell carcinoma is a rare, aggressive skin malignancy, also known as neuroendocrine carcinoma of the skin, with high rates of recurrence and distant metastasis. In refractory metastatic Merkel cell carcinoma (mMCC), besides immunotherapy, chemotherapy, and radiation, peptide receptor radionuclide therapy (PRRT) may be a viable option since this type of tumor can express somatostatin receptors. Methods: We performed a comprehensive review of the literature to evaluate the efficacy of PRRT in mMCC patients. Results: Thirty-seven patients with mMCC received PRRT (1–5 cycles) with 177Lu- or 90Y-labeled somatostatin analogs (cumulative activity, 1.5–30 GBq). Radiographic response was available for 19 of 28 patients who received PRRT alone. Six (31.6%) of 19 patients showed objective responses, from partial to complete, and no severe adverse events were reported. Conclusion: Our analysis supports the use of PRRT in mMCC with sufficient somatostatin receptor uptake, although the quality of the available evidence is low. Prospective clinical trials are already in development and have started accruing in some parts of the world.

  • PRRT
  • SSTR
  • Merkel cell carcinoma
  • theranostics
  • Lu-177

Footnotes

  • Published online Oct. 4, 2022.

View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 51 (1)
Journal of Nuclear Medicine Technology
Vol. 51, Issue 1
March 1, 2023
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review
Emran Askari, Soroush Zarehparvar Moghadam, Damian Wild, Ebrahim Delpassand, Sergio Baldari, Bernhard Nilica, Philipp E. Hartrampf, Grace Kong, Chiara Maria Grana, Martin Alexander Walter, Francesca Capoccetti, Pashtoon Murtaza Kasi, Jonathan Strosberg
Journal of Nuclear Medicine Technology Mar 2023, 51 (1) 22-25; DOI: 10.2967/jnmt.122.264904

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review
Emran Askari, Soroush Zarehparvar Moghadam, Damian Wild, Ebrahim Delpassand, Sergio Baldari, Bernhard Nilica, Philipp E. Hartrampf, Grace Kong, Chiara Maria Grana, Martin Alexander Walter, Francesca Capoccetti, Pashtoon Murtaza Kasi, Jonathan Strosberg
Journal of Nuclear Medicine Technology Mar 2023, 51 (1) 22-25; DOI: 10.2967/jnmt.122.264904
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Making the Case for Brain 18F-FDG PET Subtraction in Medically Refractory Epilepsy: A Novel, Useful Tool—Practical Points?
  • 68Ga-Pentixafor PET/CT Demonstrating In Vivo CXCR4 Receptor Overexpression in Rare Lung Malignancies: Correlation with Histologic and Histochemical Findings
Show more Brief Communication

Similar Articles

Keywords

  • PRRT
  • SSTR
  • Merkel cell carcinoma
  • theranostics
  • Lu-177
SNMMI

© 2023 Journal of Nuclear Medicine Technology

Powered by HighWire